Table 2.
CYP2C19 metabolizer phenotype and P2Y12 inhibitor at time of event or last follow-up by race and phenotype
| Patient Group | Total No. | No. (%) IM/PMs | No. (%) NM/RM/UMs | IM/PM | NM/RM/UM | ||
|---|---|---|---|---|---|---|---|
| Clopidogrel | Alternative Therapy | Clopidogrel | Alternative Therapy | ||||
| All Patients | 3342 | 1032 (30.9) | 2310 (69.1) | 461 (44.7) | 571 (55.3)† | 1932 (83.6) | 378 (16.4) |
| White | 2448 | 728 (29.7) | 1720 (70.3) | 315 (43.3) | 413 (56.7)† | 1433 (83.3) | 287 (16.7) |
| Black | 659 | 226 (34.3) | 433 (65.7) | 109 (48.2) | 117 (51.8)† | 371 (85.7) | 62 (14.3) |
| Asian, Native Hawaiian or Pacific Islander* | 43 | 20 (46.5) | 23 (53.5) | 10 (50) | 10 (50) | 19 (82.6) | 4 (17.4) |
| American Indian or Alaska Native | 36 | 17 (47.2) | 19 (52.8) | 11 (64.7) | 6 (35.3) | 13 (68.4) | 6 (31.6) |
| Multiracial | 32 | 9 (28.1) | 23 (71.9) | 5 (55.6) | 4 (44.4) | 20 (87.0) | 3 (13.0) |
| Unknown race | 124 | 32 (25.8) | 92 (74.2) | 11 (34.4) | 21 (65.6) | 76 (82.6) | 16 (17.4) |
Data are presented as number (%)
*
Combined because of the small number of Native Hawaiian or Pacific Islander patients (n=5)
†
p,0.001 for comparison of alternative therapy in IM/PMs versus NM/RM/UMs.
IM, intermediate metabolizer; NM, normal metabolizer; PM, poor metabolizer; RM, rapid metabolizer; UM, ultra-rapid metabolizer